Continuous Renal Replacement Therapy Market by Product (Disposables (Hemofilters, Bloodlines), Machine, Dialysates, Renal Replacement fluids), Modality (SCUF, CVVH, CVVHD, CVVHDF), Patient (Adult, Pediatrics, Neonates) - Global Forecast to 2026
Updated on : May 24, 2023
The global continuous renal replacement therapy market in terms of revenue was estimated to be worth $1.2 billion in 2021 and is poised to reach $1.7 billion by 2026, growing at a CAGR of 7.3% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Various factors such as the rise in worldwide prevalence of AKI, the growing number of ICU patients with AKI, the increasing incidence of sepsis, and the growing clinical advantage of continuous renal replacement therapy over intermittent blood purification are likely to boost the growth of the market.
To know about the assumptions considered for the study, Request for Free Sample Report
Continuous Renal Replacement Therapy Market Dynamics
Driver: An increase in the prevalence of acute kidney injury (AKI)
The growing worldwide incidence of AKI and AKF is, therefore, expected to increase the demand for continuous renal replacement therapy. According to the International Society of Nephrology (INR), an estimated 13.3 million cases of AKI are registered annually worldwide. This is anticipated to boost the adoption of continuous renal replacement therapy at a rapid rate. With the rapid growth in the global geriatric population, the prevalence of kidney-related diseases is expected to increase significantly. This, in turn, is expected to propel the growth of the continuous renal replacement therapy market at a significant rate during the forecast period.
Restraint: High procedural costs of continuous renal replacement therapy
As the population in emerging nations is price-sensitive, they prefer lower-priced products. Although the cost of continuous renal replacement therapy in developing countries is high, this still makes these procedures unaffordable for a large portion of the population due to their low purchasing power. This limits the demand for and uptake of continuous renal replacement therapy in both developing and developed countries.
Opportunity: Emerging markets in APAC and RoW
Emerging markets such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities for players in the continuous renal replacement therapy market. According to a study conducted on 100 critically ill patients in a prospective observational study published in the Journal of Clinical and Diagnostic Research (JCDR) 2018, AKI was observed in 17.3 cases per 1,000 people in India. To leverage the significant growth opportunities in emerging countries, players are increasingly focusing on undertaking strategic developments to increase their presence in these markets and tap a large number of customers. Additionally, regulatory policies in the Asia-Pacific region are more adaptive and business-friendly due to the less-stringent data requirements. This, along with the increasing competition in the mature markets (Europe, Japan, and Australia), will further encourage manufacturers of continuous renal replacement therapy products to focus on the emerging markets.
Challenge: Shortage of trained ICU professionals in developing nations
Continuous renal replacement therapy is a highly specialised and critical therapy that involves complex nursing care. Properly trained ICU nurses are required for the continuous assessment of indications, ensuring good vascular access, avoiding unnecessary interruptions, and preventing complications in patients during continuous renal replacement therapy. However, currently, there is a dearth of registered nurses in ICU settings. Moreover, the complexity associated with continuous renal replacement therapy is likely to hinder market growth.
Dialysates and replacement fluids were the dominant product segment in the continuous renal replacement therapy market.
The dominant market position of this segment is attributed to increased market availability and demand for novel product lines for dialysates, along with the emergence of local players and startups offering cost-effective and affordable products.
Continuous venovenous hemodiafiltration (CVVHDF) was the fastest-growing continuous renal replacement therapy modality globally.
The high growth rate of the CVVHDF segment can be attributed to its procedural flexibility as well as other advantages, such as diffusion for the removal of solutes, as compared to other modes.
Adult patients were the larger patient segment as compared to paediatric patients in the continuous renal replacement therapy market.
Adult and geriatric patients are the largest target group for continuous renal replacement therapy products, owing to higher prevalence and hospital admissions among them for AKI and other critical conditions, as well as the greater focus of leading players on adult and geriatric-specific product portfolios.
Asia-Pacific is the fastest-growing region in the continuous renal replacement therapy market.
The global market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2021, Asia-Pacific is reported to be the fastest-growing region owing to the increasing incidence and prevalence of AKI, the rising approval of continuous renal replacement therapy products for multiple applications, and continued government initiatives to increase awareness about the advancements in renal therapy.
To know about the assumptions considered for the study, download the pdf brochure
Prominent players in this market are Baxter International Inc. (US), Fresenius Medical Care AG & Co. KGaA (Germany), NIKKISO CO., LTD. (Japan), B. Braun Melsungen AG (Germany), Asahi Kasei Corporation (Japan), and Toray Medical Co., Ltd. (Japan), among others.
Continuous Renal Replacement Therapy Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2021 |
$1.2 billion |
|
Projected Revenue by 2026 |
$1.7 billion |
|
Revenue Rate |
Poised to grow at a CAGR of 7.3 % |
|
Market Driver |
An increase in the prevalence of acute kidney injury (AKI) |
|
Market Opportunity |
Emerging markets in APAC and RoW |
This research report categorizes the continuous renal replacement therapy market to forecast revenue and analyze trends in each of the following submarkets:
By Product
- Dialysates and Replacement Fluids
- Disposables
- Hemofilters
- Bloodline Sets & Tubes
- Other Disposables
- CRRT Systems
By Modality
- Continuous venovenous hemofiltration (CVVH)
- Continuous venovenous hemodiafiltration (CVVHDF)
- Continuous venovenous haemodialysis (CVVHD)
- Slow continuous ultrafiltration (SCUF)
By Age group
- Adults
- Pediatrics /Neonates
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- RoEU
-
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- RoAPAC
-
Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
Recent Developments
- Fresenius Medical Care introduced its Speedswap system in American markets in 2022, allowing for the simple replacement of flow-compromising dialysis filters without the need for cartridge replacement.
- Fresenius Medical Care, in collaboration with the National Kidney Foundation (Malaysia), launched the Kidney Health Initiative in 2022, with the goal of raising awareness among adult and paediatric patients and promoting kidney health in Malaysia.
- In 2020, Medtronic plc announced the launch of the Carpediem system, the first and only paediatric and neonatal acute dialysis system designed to treat patients weighing 2.5–10 kg (5.5–22 pounds) requiring renal replacement therapy.
Frequently Asked Questions (FAQ):
How big is the global continuous renal replacement therapy market?
Global continuous renal replacement therapy market revenue was estimated at $1.2 billion in 2021 and is projected to reach $1.7 billion by 2026, with a robust growth rate of 7.3% CAGR from 2021 to 2026.
Which major factors are influencing global growth of continuous renal replacement therapy market?
Various factors such as the rise in worldwide prevalence of AKI, the growing number of ICU patients with AKI, the increasing incidence of sepsis, and the growing clinical advantage of continuous renal replacement therapy over intermittent blood purification are likely to boost the growth of the market.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 25)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR MARKET STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 29)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 USAGE-BASED MARKET ESTIMATION
FIGURE 4 ESTIMATION OF CRRT PROCEDURES
FIGURE 5 MARKET SIZE ESTIMATION: GLOBAL MARKET BASED ON PRODUCT UTILIZATION METHODOLOGY
FIGURE 6 MARKET SIZE ESTIMATION: GLOBAL MARKET BASED ON REVENUE MAPPING METHODOLOGY
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 39)
FIGURE 8 CRRT MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
FIGURE 9 GLOBAL MARKET, BY MODALITY, 2021 VS. 2026 (USD MILLION)
FIGURE 10 GLOBAL MARKET, BY AGE GROUP, 2021 VS. 2026 (USD MILLION)
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL MARKET
4 PREMIUM INSIGHTS (Page No. - 43)
4.1 CRRT MARKET OVERVIEW
FIGURE 12 RISING PREVALENCE OF AKI AND GROWING AWARENESS ABOUT CRRT TO DRIVE MARKET GROWTH
4.2 GLOBAL MARKET SHARE, BY AGE GROUP, 2021
FIGURE 13 ADULTS SEGMENT TO DOMINATE THE GLOBAL MARKET IN 2021
4.3 ASIA PACIFIC: MARKET, BY PRODUCT AND COUNTRY
FIGURE 14 DIALYSATES AND REPLACEMENT FLUIDS ACCOUNT FOR THE LARGEST SHARE OF THE CRRT PRODUCTS MARKET IN THE APAC
FIGURE 15 APAC MARKET TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2021–2026)
5 MARKET OVERVIEW (Page No. - 47)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 16 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of acute kidney injury (AKI)
FIGURE 17 GLOBAL INCIDENCE OF AKI, 2010 VS. 2015 VS. 2020
TABLE 1 NUMBER OF PEOPLE AGED 65 YEARS OR OVER, BY REGION, 2019 VS. 2050
5.2.1.2 Growing number of ICU patients with AKI and increasing incidence of sepsis
FIGURE 18 IMPACT OF ICU-ACQUIRED AKI IN THE US
5.2.1.3 Increasing clinical advantage of CRRT over intermittent blood purification
5.2.1.4 Technological advancements and new product launches
5.2.1.5 Growing prevalence of diabetes and hypertension
FIGURE 19 TOP 5 COUNTRIES WITH CHILDREN AND ADOLESCENTS WITH TYPE I DIABETES, 2019
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulatory guidelines in North America
5.2.2.2 High procedural cost of CRRT
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets in APAC and RoW
5.2.3.2 Increasing applications of CRRT
5.2.3.2.1 Evolution of CRRT from a simple renal replacement treatment to multi-organ support therapy
5.2.3.2.2 Progression of CRRT from adaptive renal devices to multipurpose treatment machines
5.2.3.3 Ongoing research to establish the safety and efficacy profile of CRRT
5.2.3.4 Development of CRRT systems for pediatric patients
5.2.3.4.1 The CARPEDIEM Project
5.2.3.5 Untapped growth opportunities in North America
5.2.4 CHALLENGES
5.2.4.1 High complexity of CRRT
5.2.4.2 Lack of standard treatment guidelines in developing nations
5.2.4.3 Shortage of trained ICU professionals in developing nations
5.2.4.4 Poor reimbursement scenario in developing countries
5.2.4.5 Lack of awareness about the benefits of CRRT
5.3 GLOBAL REGULATORY LANDSCAPE
5.3.1 NORTH AMERICA
5.3.2 EUROPE
5.3.3 ASIA PACIFIC
5.3.3.1 India
5.3.3.2 China
5.3.3.3 Japan
5.3.3.4 South Korea
5.3.4 REST OF THE WORLD (ROW)
5.3.4.1 Brazil
5.3.4.2 Argentina
5.4 GLOBAL REIMBURSEMENT SCENARIO
5.4.1 NORTH AMERICA
5.4.2 EUROPE
5.4.3 ASIA PACIFIC
5.4.4 JAPAN
5.4.5 REST OF THE WORLD (ROW)
5.4.5.1 Brazil
5.4.5.2 Central America and the Caribbean
5.5 COVID-19 IMPACT ON THE CRRT MARKET
FIGURE 20 US: COVID-19 HOSPITALIZATION DATA FOR SPECIALIZED MEDICAL CONDITIONS IN ADULTS (AS OF APRIL 11, 2020)
5.6 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN OF THE GLOBAL MARKET
5.7 ECOSYSTEM COVERAGE
5.8 PRICING TREND ANALYSIS
TABLE 2 AVERAGE PRICE OF CRRT SYSTEMS AND CONSUMABLES, BY COUNTRY, 2020 (USD)
5.9 PORTER’S FIVE FORCES ANALYSIS
TABLE 3 GLOBAL MARKET: PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT FROM NEW ENTRANTS
FIGURE 22 THREAT FROM NEW ENTRANTS
5.9.2 THREAT FROM SUBSTITUTES
FIGURE 23 THREAT FROM SUBSTITUTES
5.9.3 BARGAINING POWER OF SUPPLIERS
FIGURE 24 BARGAINING POWER OF SUPPLIERS
5.9.4 BARGAINING POWER OF BUYERS
FIGURE 25 BARGAINING POWER OF BUYERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
FIGURE 26 INTENSITY OF COMPETITIVE RIVALRY
6 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT (Page No. - 69)
6.1 INTRODUCTION
TABLE 4 GLOBAL MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
6.2 DIALYSATES & REPLACEMENT FLUIDS
6.2.1 RISING DEMAND FOR DIALYSATES HAS SUPPORTED MARKET GROWTH
TABLE 5 DIALYSATES & REPLACEMENT FLUIDS MARKET, BY MODALITY, 2019–2026 (USD MILLION)
TABLE 6 DIALYSATES & REPLACEMENT FLUIDS MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
TABLE 7 DIALYSATES & REPLACEMENT FLUIDS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3 DISPOSABLES
TABLE 8 DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 9 DISPOSABLES MARKET, BY MODALITY, 2019–2026 (USD MILLION)
TABLE 10 DISPOSABLES MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
TABLE 11 DISPOSABLES MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3.1 HEMOFILTERS
6.3.1.1 Hemofilters are widely adopted during CRRT procedures for the treatment of AKI
TABLE 12 HEMOFILTERS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 13 HEMOFILTERS MARKET, BY MODALITY, 2019–2026 (USD MILLION)
TABLE 14 HEMOFILTERS MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
6.3.2 BLOODLINE SETS & TUBES
6.3.2.1 Established players are focusing on strengthening their bloodline sets and tubes product lines
TABLE 15 BLOODLINE SETS & TUBES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 16 BLOODLINE SETS & TUBES MARKET, BY MODALITY, 2019–2026 (USD MILLION)
TABLE 17 BLOODLINE SETS & TUBES MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
6.3.3 OTHER DISPOSABLES
TABLE 18 OTHER DISPOSABLES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 19 OTHER DISPOSABLES MARKET, BY MODALITY, 2019–2026 (USD MILLION)
TABLE 20 OTHER DISPOSABLES MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
6.4 CRRT SYSTEMS
6.4.1 INTRODUCTION OF ADVANCED PRODUCTS TO DRIVE THE DEMAND FOR CRRT SYSTEMS
TABLE 21 CRRT SYSTEMS MARKET, BY MODALITY, 2019–2026 (USD MILLION)
TABLE 22 CRRT SYSTEMS MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
TABLE 23 CRRT SYSTEMS MARKET BY REGION, 2019–2026 (USD MILLION)
7 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY (Page No. - 80)
7.1 INTRODUCTION
TABLE 24 GLOBAL MARKET, BY MODALITY, 2019–2026 (USD MILLION)
7.2 CONTINUOUS VENOVENOUS HEMOFILTRATION
7.2.1 WIDESPREAD ADOPTION OF CVVH IN THE TREATMENT OF ACUTE KIDNEY INJURY TO DRIVE MARKET GROWTH
TABLE 25 CONTINUOUS VENOVENOUS HEMOFILTRATION MARKET, BY REGION, 2019–2026 (USD MILLION)
7.3 CONTINUOUS VENOVENOUS HEMODIAFILTRATION
7.3.1 CVVHDF IS USED IN PATIENTS WITH CONGESTIVE HEART FAILURE
TABLE 26 CONTINUOUS VENOVENOUS HEMODIAFILTRATION MARKET, BY REGION, 2019–2026 (USD MILLION)
7.4 CONTINUOUS VENOVENOUS HEMODIALYSIS
7.4.1 THIS THERAPY IS MORE EFFECTIVE IN REMOVING SMALL TO MEDIUM-SIZED MOLECULES AS COMPARED TO OTHER CRRT MODALITIES
TABLE 27 CONTINUOUS VENOVENOUS HEMODIALYSIS MARKET, BY REGION, 2019–2026 (USD MILLION)
7.5 SLOW CONTINUOUS ULTRAFILTRATION
7.5.1 SCUF DOES NOT USE DIALYSATES OR REPLACEMENT FLUIDS FOR THE REMOVAL OF EXCESS FLUID FROM THE BLOODSTREAM
TABLE 28 SLOW CONTINUOUS ULTRAFILTRATION MARKET, BY REGION, 2019–2026 (USD MILLION)
8 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP (Page No. - 86)
8.1 INTRODUCTION
TABLE 29 GLOBAL MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
8.2 ADULTS
8.2.1 ADULTS HOLD THE LARGEST SHARE OF THE MARKET BY AGE GROUP
TABLE 30 GLOBAL MARKET FOR ADULTS, BY REGION, 2019–2026 (USD MILLION)
8.3 PEDIATRICS & NEONATES
8.3.1 HIGH PREVALENCE OF AKI IN NEONATES TO AID THE MARKET GROWTH DURING THE FORECAST PERIOD
TABLE 31 GLOBAL MARKET FOR PEDIATRICS & NEONATES, BY REGION, 2019–2026 (USD MILLION)
9 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION (Page No. - 90)
9.1 INTRODUCTION
TABLE 32 GLOBAL MARKET, BY REGION, 2019–2026 (USD MILLION)
9.2 EUROPE
FIGURE 27 EUROPE: CRRT MARKET SNAPSHOT
TABLE 33 EUROPE: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 34 EUROPE: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 35 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 36 EUROPE: MARKET, BY MODALITY, 2019–2026 (USD MILLION)
TABLE 37 EUROPE: MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
9.2.1 GERMANY
9.2.1.1 Germany is the largest market for continuous renal replacement therapy in Europe
TABLE 38 GERMANY: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 39 GERMANY: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
9.2.2 UK
9.2.2.1 Rising number of sepsis cases in the UK to support market growth
TABLE 40 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 41 UK: CRRT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
9.2.3 FRANCE
9.2.3.1 France is the fastest-growing market for CRRT in Europe
TABLE 42 FRANCE: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 43 FRANCE: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
9.2.4 ITALY
9.2.4.1 Government initiatives to promote the awareness of CRRT for renal care to drive market growth
TABLE 44 ITALY: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 45 ITALY: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION
9.2.5 SPAIN
9.2.5.1 Favorable reimbursement scenario to favor market growth
TABLE 46 SPAIN: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 47 SPAIN: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
9.2.6 REST OF EUROPE
TABLE 48 ROE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 49 ROE: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
9.3 NORTH AMERICA
TABLE 50 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 51 NORTH AMERICA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 52 NORTH AMERICA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 53 NORTH AMERICA: MARKET, BY MODALITY, 2019–2026 (USD MILLION)
TABLE 54 NORTH AMERICA: CRRT MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
9.3.1 US
9.3.1.1 Large number of AKI patients in the region to drive the market growth
TABLE 55 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 56 US: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
9.3.2 CANADA
9.3.2.1 High cost of CRRT as compared to IHD is negatively impacting market growth in Canada
TABLE 57 CANADA: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 58 CANADA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 28 APAC: CRRT MARKET SNAPSHOT
TABLE 59 APAC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 60 APAC: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 61 APAC: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 62 APAC: MARKET, BY MODALITY, 2019–2026 (USD MILLION)
TABLE 63 APAC: CRRT MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
9.4.1 JAPAN
9.4.1.1 Increasing use of CRRT to boost the market in Japan
TABLE 64 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 65 JAPAN: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
9.4.2 CHINA
9.4.2.1 Increasing prevalence of ESRD and AKI to boost the demand for CRRT
TABLE 66 CHINA: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 67 CHINA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Growing number of AKI patients and ICU admissions to support market growth
TABLE 68 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 69 INDIA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
9.4.4 AUSTRALIA
9.4.4.1 The Australian government is taking various initiatives to increase the awareness of CRRT
TABLE 70 AUSTRALIA: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 71 AUSTRALIA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
9.4.5 SOUTH KOREA
9.4.5.1 The country is witnessing an increasing number of patients receiving CRRT for the treatment of AKI
TABLE 72 SOUTH KOREA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 73 SOUTH KOREA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
9.4.6 REST OF ASIA PACIFIC
TABLE 74 REST OF ASIA PACIFIC: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 75 REST OF ASIA PACIFIC: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
9.5 LATIN AMERICA
TABLE 76 LATIN AMERICA: CRRT MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 77 LATIN AMERICA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 78 LATIN AMERICA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 79 LATIN AMERICA: MARKET, BY MODALITY, 2019–2026 (USD MILLION)
TABLE 80 LATIN AMERICA: MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
9.5.1 BRAZIL
9.5.1.1 Brazil holds the largest share in the Latin American CRRT market
TABLE 81 BRAZIL: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 82 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
9.5.2 MEXICO
9.5.2.1 Large patient population and growing middle-class population to support market growth in Mexico
TABLE 83 MEXICO: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 84 MEXICO: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
9.5.3 REST OF LATIN AMERICA
TABLE 85 REST OF LATIN AMERICA: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 86 REST OF LATIN AMERICA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 LACK OF AWARENESS REGARDING CRRT TO RESTRAIN THE MARKET GROWTH IN THE REGION
TABLE 87 MEA: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 88 MEA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 89 MEA: MARKET, BY MODALITY, 2019–2026 (USD MILLION)
TABLE 90 MEA: MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 125)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES
10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
FIGURE 29 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE CRRT MARKET
10.4 GLOBAL MARKET SHARE ANALYSIS (2020)
TABLE 91 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DEGREE OF COMPETITION
10.5 COMPETITIVE LEADERSHIP MAPPING
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
FIGURE 30 GLOBAL MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
10.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2020)
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
FIGURE 31 GLOBAL MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2020
10.7 FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE GLOBAL MARKET
10.7.1 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE GLOBAL MARKET
TABLE 92 INDUSTRY FOOTPRINT OF COMPANIES
TABLE 93 REGIONAL FOOTPRINT OF COMPANIES
10.7.1.1 CRRT market: Product launches and regulatory approvals (January 2018 to May 2021)
TABLE 94 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
10.7.1.2 CRRT market: Deals (January 2018 to May 2021)
TABLE 95 KEY DEALS
10.7.1.3 Continuous renal replacement therapy market: Other developments (January 2018 to May 2021)
TABLE 96 KEY OTHER DEVELOPMENTS
11 COMPANY PROFILES (Page No. - 137)
11.1 MAJOR PLAYERS
11.1.1 BAXTER INTERNATIONAL INC.
11.1.1.1 Business overview
TABLE 97 BAXTER INTERNATIONAL INC.: BUSINESS OVERVIEW
FIGURE 32 COMPANY SNAPSHOT: BAXTER INTERNATIONAL INC.
11.1.1.2 Products offered
TABLE 98 BAXTER INTERNATIONAL INC.: PRODUCT OFFERINGS
11.1.1.3 Recent developments
11.1.1.4 MnM view
11.1.2 FRESENIUS MEDICAL CARE AG & CO. KGAA
11.1.2.1 Business overview
TABLE 99 FRESENIUS MEDICAL CARE AG & CO. KGAA: BUSINESS OVERVIEW
FIGURE 33 COMPANY SNAPSHOT: FRESENIUS MEDICAL CARE AG & CO. KGAA
11.1.2.2 Products offered
TABLE 100 FRESENIUS MEDICAL CARE AG & CO. KGAA: PRODUCT OFFERINGS
11.1.2.3 Recent developments
11.1.2.4 MnM view
11.1.3 NIKKISO CO., LTD.
11.1.3.1 Business overview
TABLE 101 NIKKISO CO., LTD.: BUSINESS OVERVIEW
FIGURE 34 COMPANY SNAPSHOT: NIKKISO CO., LTD.
11.1.3.2 Products offered
TABLE 102 NIKKISO CO., LTD.: PRODUCT OFFERINGS
11.1.3.3 MnM view
11.1.4 B. BRAUN MELSUNGEN AG
11.1.4.1 Business overview
TABLE 103 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
FIGURE 35 COMPANY SNAPSHOT: B. BRAUN MELSUNGEN AG
11.1.4.2 Products offered
TABLE 104 B. BRAUN MELSUNGEN AG: PRODUCT OFFERINGS
11.1.4.3 Recent developments
11.1.4.4 MnM view
11.1.5 MEDTRONIC PLC
11.1.5.1 Business overview
TABLE 105 MEDTRONIC PLC: BUSINESS OVERVIEW
FIGURE 36 COMPANY SNAPSHOT: MEDTRONIC PLC
11.1.5.2 Products offered
TABLE 106 MEDTRONIC PLC: PRODUCT OFFERINGS
11.1.5.3 Recent developments
11.1.6 ASAHI KASEI CORPORATION
11.1.6.1 Business overview
TABLE 107 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
FIGURE 37 COMPANY SNAPSHOT: ASAHI KASEI CORPORATION
11.1.6.2 Products offered
TABLE 108 ASAHI KASEI CORPORATION: PRODUCT OFFERINGS
11.1.7 TORAY MEDICAL CO., LTD.
11.1.7.1 Business overview
TABLE 109 TORAY MEDICAL CO., LTD.: BUSINESS OVERVIEW
FIGURE 38 COMPANY SNAPSHOT: TORAY MEDICAL CO., LTD.
11.1.7.2 Products offered
TABLE 110 TORAY MEDICAL CO., LTD.: PRODUCT OFFERINGS
11.1.8 NIPRO CORPORATION
11.1.8.1 Business overview
TABLE 111 NIPRO CORPORATION: BUSINESS OVERVIEW
FIGURE 39 COMPANY SNAPSHOT: NIPRO CORPORATION
11.1.8.2 Products offered
TABLE 112 NIPRO CORPORATION: PRODUCT OFFERINGS
11.1.8.3 Recent developments
11.1.9 INFOMED SA
11.1.9.1 Business overview
TABLE 113 INFOMED SA: BUSINESS OVERVIEW
11.1.9.2 Products offered
TABLE 114 INFOMED SA: PRODUCT OFFERINGS
11.1.9.3 Recent developments
11.1.9.4 MnM view
11.1.10 MEDICA SPA
11.1.10.1 Business overview
TABLE 115 MEDICA SPA: BUSINESS OVERVIEW
11.1.10.2 Products offered
TABLE 116 MEDICA SPA: PRODUCT OFFERINGS
11.1.11 MEDITES PHARMA SPOL. S.R.O
11.1.11.1 Business overview
TABLE 117 MEDITES PHARMA SPOL. S.R.O: BUSINESS OVERVIEW
11.1.11.2 Products offered
TABLE 118 MEDITES PHARMA SPOL. S.R.O: PRODUCT OFFERINGS
11.1.12 MEDICAL COMPONENTS, INC.
11.1.12.1 Business overview
TABLE 119 MEDICAL COMPONENTS, INC.: BUSINESS OVERVIEW
11.1.12.2 Products offered
TABLE 120 MEDICAL COMPONENTS, INC.: PRODUCT OFFERINGS
11.1.13 SWS HEMODIALYSIS CARE CO. LTD.
11.1.13.1 Business overview
TABLE 121 SWS HEMODIALYSIS CARE CO. LTD.: BUSINESS OVERVIEW
11.1.13.2 Products offered
TABLE 122 SWS HEMODIALYSIS CARE CO. LTD.: PRODUCT OFFERINGS
11.1.13.3 Recent developments
11.1.14 NINGBO TIANYI MEDICAL DEVICES CO., LTD.
11.1.14.1 Business overview
TABLE 123 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: BUSINESS OVERVIEW
11.1.14.2 Products offered
TABLE 124 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: PRODUCT OFFERINGS
11.1.15 ANJUE MEDICAL EQUIPMENT CO., LTD.
11.1.15.1 Business overview
TABLE 125 ANJUE MEDICAL EQUIPMENT CO., LTD.: BUSINESS OVERVIEW
11.1.15.2 Products offered
TABLE 126 ANJUE MEDICAL EQUIPMENT CO., LTD.: PRODUCT OFFERINGS
11.2 EMERGING PLAYERS
11.2.1 KIMAL
11.2.2 JIANGXI SANXIN MEDTEC CO., LTD.
11.2.3 ALLMED MEDICAL PRODUCTS CO., LTD.
11.2.4 DIALCO MEDICAL INC.
11.2.5 BROWNDOVE HEALTHCARE PVT. LTD.
12 APPENDIX (Page No. - 174)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
The study involved four major activities to estimate the current size of the continuous renal replacement therapy market. Extensive secondary research was carried out to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources, such as annual reports, press releases, and investor presentations of companies, white papers, certified publications, articles by recognized authors, regulatory bodies, and publications from government sources [such as the National Institutes of Health (NIH), the US Food and Drug Administration (FDA), the US Census Bureau, the World Health Organization (WHO), the American Society of Nephrology (ASN), the American Association of Kidney Patients (AAKP), and the European Renal Association] were referred to identify and collect information for the continuous renal replacement therapy market study.
Primary Research
The continuous renal replacement therapy market comprises several stakeholders, such as manufacturers of CRRT machines, CRRT disposables, dialysates, and replacement fluids, as well as market research and consulting firms. The demand side of this market is characterized by increasing AKI, growing awareness of CRRT, and an increased number of players in the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is the breakdown of primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the continuous renal replacement therapy market. These methods were also extensively used to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research.
- The industry's supply chain and market size, in terms of value, have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation
After arriving at the overall size of the global continuous renal replacement therapy market through the above-mentioned methodology, this market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. Market data was triangulated by studying various macroindicators and regional trends from both demand- and supply-side participants.
Report Objectives
- To define, describe, and forecast the global continuous renal replacement therapy market on the basis of product, modality, age group and region.
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
- To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa
- To profile the key market players and comprehensively analyze their market shares and core competencies2
- To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global continuous renal replacement therapy market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the global continuous renal replacement therapy market report
Product Analysis
- Product Matrix, which gives a detailed comparison of the product portfolios of the top five global players.
Company Information
- Detailed analysis and profiling of additional market players (up to 5 OEMs)
Geographic Analysis
- Further breakdown of the Rest of Europe continuous renal replacement therapy market into Belgium, Austria,
- Denmark, Greece, Poland, and Russia, among other countries
- Further breakdown of the Rest of Asia Pacific continuous renal replacement therapy market into New Zealand, Vietnam, Philippines, Singapore, Malaysia, Thailand, and Indonesia, among other countries
- Further breakdown of the Rest of Latin America continuous renal replacement therapy market into Argentina, and Colombia, among other countries.
Generating Response ...
Growth opportunities and latent adjacency in Continuous Renal Replacement Therapy Market